Advertisement

European Journal of Clinical Pharmacology

, Volume 7, Issue 5, pp 321–330 | Cite as

Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus

  • P. Heine
  • H. Kewitz
  • U. Schnapperelle
Originals

Summary

Using a new procedure to study the dose-response relationships of sulphonylureas, the effects of tolbutamide and glibenclamide on blood sugar and serum insulin have been examined in 9 diabetic patients. Particular changes sought in serum insulin were alteration in the two initial peaks, elevation of basal levels and augmentation of the response to glucose infusions. In general, both sulphonylureas had identical effects and glibenclamide was not superior to tolbutamide. In 3 or 4 obese patients the first of the two initial insulin peaks was as high as in healthy volunteers, whereas the second peak was diminished; both initial peaks were greatly reduced in non-obses patients. The basal level of insulin was elevated in only one patient after glibenclamide. The response of insulin levels to glucose infusions was not increased in any patient and was actually inhibited by glibenclamide in one case. Tolbutamide produced its maximal effects after a dose of 1.0 g, glibenclamide after 1 mg. Blood sugar levels declined more rapidly in patients with latent diabetes than in those with the overt disease. In two of the latter, the fall in blood sugar was not associated with a corresponding increase in serum insulin.

Key words

Dose-response relationship tolbutamide glibenclamide diabetes mellitus intravenous glucose test 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Behringer, A., Hrabal, I., Irsigler, K., Thaler, H.: The effect of tolbutamide on the diabetic fatty liver. Germ. Med. Mth.13, 595–598 (1968)Google Scholar
  2. 2.
    Berchtold, P., Büber, V., Meier, V., Fleber, J.-P., Keiser, G.: Vergleichende Untersuchungen über den oralen und intravenösen Tolbutamidtest. — II. Bestimmung von Glukose, Serum-Insulin und Serum-Tolbutamid bei normalen, jungen Probanden. Diabetologia7, 77–81 (1971)Google Scholar
  3. 3.
    Boden, G., Soeldner, J.S., Gleason, R.E., Marble, A.: Elevated serum human growth hormone and decreased serum insulin in prediabetic males after intravenous tolbutamide and glucose. J. clin. Invest.47, 729–739 (1968)Google Scholar
  4. 4.
    Butterfield, W.J.H., Whichelow, M.J.: Effect of diet, sulfonylureas, and phenformin on peripheral glucose uptake in diabetes and obesity. Lancet1968 II, 785–788Google Scholar
  5. 5.
    Cahill, G.F.: Effects of substituted sulfonylureas on rat diaphragma and liver tissue. Diabetes6, 26–27 (1957)Google Scholar
  6. 6.
    Cordes, U., Sell, G., Beyer, J., Haupt, E., Schöffling, K.: Various effects of glibenclamide, tolbutamide, and insulin on epinephrine secretion following adrenergic blockade. Diabetologia9, 64 (1973)Google Scholar
  7. 7.
    Cowell, Jr., A.R.: Potentiation of insulin action on the liver by tolbutamide. Metabolism13, 1310–1317 (1964)Google Scholar
  8. 8.
    Feldman, J.M., Lebovitz, H.E.: Endocrine and metabolic effects of glibenclamide. Evidence for an extrapancreatic mechanism of action. Diabetes20, 745–755 (1971)Google Scholar
  9. 9.
    Fußgänger, R.D.: Die Rolle des Glucagons bei der Zuckerkrankheit. Deutsch. med. J.23, 601–608 (1972)Google Scholar
  10. 10.
    Hasselblatt, A., Panten, U., Poser, W.: Wirkungen von Tolbutamid und HB 419 auf Blutglukose, Plasma-Corticosteron und Leberglykogen bei der Ratte. Arzneimittel-Forsch.19, 1483–1487 (1969)Google Scholar
  11. 11.
    Haupt, E., Köberich, W., Beyer, J., Schöffling, K.: Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride, and glisoxepide. — II. Repeated administration in combination with glucose. Diabetologia7, 455–460 (1971)Google Scholar
  12. 12.
    Kewitz, H., Schnapperelle, U., Heine, P.: Dose-effect-relationship of tolbutamide at different blood glucose levels in healthy volunteers. 14. Frühjahrstagung der Deutschen Pharmakologischen Gesellschaft, Mainz 18.–21. März 1973Google Scholar
  13. 13.
    Karman, H., Mialhe, P.: Glucose-glucagon feed-back mechanism in normal and diabetic geese and ducks. Diabetologia9, 74 (1973)Google Scholar
  14. 14.
    Marshall, A., Gingerich, R.L., Wright, P.H.: Hepatic effects of sulfonylureas. Metabolism19, 1046–1052 (1970)Google Scholar
  15. 15.
    Meade, C.R., Klitgaard, H.M.: A simplified method for immuno-assay of human serum insulin. J. nucl. Med.3, 407–416 (1962)Google Scholar
  16. 16.
    Melani, F., Dischuneit, H., Bartelt, K.M., Friedrich, H., Pfeiffer, E.F.: Über die radioimmunologische Bestimmung von Insulin im Blut. Klin. Wschr.43, 1000–1007 (1965)Google Scholar
  17. 17.
    Ohneda, A., Parada, E., Eisentraut, A.M., Unger, R.H.: Characterization of response of circulating glucagon to intraduodenal and intravenous administration of amino acids. J. clin. Invest.47, 2305–2322 (1968)Google Scholar
  18. 18.
    Raptis, S., Pfeiffer, E.F.: Sulfonylharnstoffe als orale Antidiabetika der 1. und 2. Generation. Therapiewoche21, 578 (1971)Google Scholar
  19. 19.
    Reaven, G., Dray, J.: Effect of chlorpropamide on serum glucose and immunoreactive insulin concentrations in patients with maturity-onset diabetes mellitus. Diabetes16, 487–492 (1967)Google Scholar
  20. 20.
    Samols, E., Tyler, J.M., Mialhe, P: Suppression of pancreatic glucagon release by the hypoglycaemic sulphonylureas. Lancet1969 I, 174–176Google Scholar
  21. 21.
    Schöffling, K., Haupt, E., Köberich, W., Beyer, J.: Neuere Erkenntnisse bei der Anwendung von blutzuckersenkenden Sulfonamiden der ersten und zweiten Generation. Klin. Wschr.51, 68–77 (1973)Google Scholar
  22. 22.
    Schmidt, F.H.: Die enzymatische Bestimmung von Glukose und Fruktose nebeneinander. Klin. Wschr.39, 1244–1247 (1961)Google Scholar
  23. 23.
    Schmidt, F.H.: Enzymatische Methoden zur Bestimmung von Blut- und Harnzucker unter Berücksichtigung von Vergleichsuntersuchungen mit klassischen Methoden. Internist4, 554–559 (1963)Google Scholar
  24. 24.
    Spingler, H.: Über eine Möglichkeit zur colorimetrischen Bestimmung von N-(4-Methyl-benzol-sulfonyl)-N′-butyl-harnstoff im Serum. Klin. Wschr.35, 533–535 (1957)Google Scholar
  25. 25.
    Unger, R.H.: Glucagon and the insulin: glucagon ratio in diabetes and other catabolic illnesses. Diabetes20, 834–838 (1971)Google Scholar

Copyright information

© Springer-Verlag 1974

Authors and Affiliations

  • P. Heine
    • 1
  • H. Kewitz
    • 1
  • U. Schnapperelle
    • 1
  1. 1.Institute of Clinical PharmacologyFree University of Berlin, Klinikum SteglitzBerlinGermany

Personalised recommendations